RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models.
Molekulargewicht:
1012.26
Reinheit:
98.73%
CAS Nummer:
[2641998-63-0]
Formel:
C55H78FN9O8
Target-Kategorie:
ERK,Kras,Ras,Apoptosis
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten